NEW YORK (GenomeWeb) – Protagen said today that it has granted a semi-exclusive license to San Diego-based Inova Diagnostics for its systemic sclerosis biomarker BICD2.

The license allows Inova to include BICD2 in its portfolio of connective tissue disease reagents aimed at aiding in the diagnosis of systemic sclerosis. Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.